|
|
|
|
Amgen Inc. - Financial and Strategic Analysis Review
Summary Amgen Inc.(Amgen) is a biotechnology company that is focused on the discovery, development, manufacturing and marketing of human therapeutics based on advances in cellular and molecular biology. The company...
|
|
|
Myriad Genetics Posts Preliminary Results For Q4,09
Company anticipates revenue of $86 million for fourth quarter ending June 2009 Related News Nplates plenectomised adult chronic immune thrombocytopenic purpura (ITP) ...Amgen, a biotechnology company, is exercising an option to...
|
|
|
Is IBB the Best Biotech ETF?
Healthcare has dominated the headlines in recent weeks, as President Obama presents his new proposals and the industry recovers from a position where it was perhaps oversold.Where, in this mix, are ETFs the most helpful? iShares Nasdaq...
|
|
|
Is IBB the Best Biotech ETF
Healthcare has dominated the headlines in recent weeks, as President Obama presents his new proposals and the industry recovers from a position where it was perhaps oversold.Where, in this mix, are ETFs the most helpful? iShares Nasdaq...
|
|
|
Gyros AB raises 7.5M for biopharma development technology
which specialises in automated micro-immunoassays for developing protein drugs, has raised SEK 80 million (7.5 million) in a fundraising led by SLS Invest, the leading shareholder.The new funds will enableto drive the further...
|
|
|
RCW Opens Umbrella, Finds Self Under It
Regan Campbell Ward - McCann announces a major restructuring.The agencys various operating units will now be organized under a new name, RCW GROUP. We see this restructuring as providing immediate benefits to our clients, said RCW...
|
|
|
Amgens Denosumab Gets August Panel
The FDAs Reproductive Health Drugs Advisory Committee will consider Amgens BLA for its osteoporosis drug denosumab at an Aug.13 meeting. Amgens Denosumab Gets August Panel.
|
|
|
Arthritis meds need comparing, IOM says
Quick, what's at the top of the list for comparative-effectiveness research?Right, those expensive biologic anti-inflammatory meds, namely Enbrel (Amgen and Wyeth), Remicade and Simponi (Johnson & Johnson and Schering-Plough...
|
|
|
Genzyme: The Next Big Biotech Machine
Genzyme (GENZ), which had a very broad range of treatment catering to numerous niche markets, is the company Im making reference to.This strategy was unprecedented until recently as the company targets those diseases that strike a very...
|
|
|
Option Skews - Relatively Heavy Call Activity on Citigroup Inc, Bank of America Corp, Research in Motion Limit
Here are the stocks seeing a bias toward call activity on Tuesday.This filtered scan is based on the International Securities Exchange (ISE) buy-to-open data. It looks for stocks where the previous day's call volume on the ISE is at...
|
|
|
Jury finds Abbott infringed on J&J's patent; Abbott plans to appeal $1.67B ruling
Jury finds Abbott infringed on J&J's patent; Abbott plans to appeal $1.67B ruling NEW YORK - Abbott Laboratories plans to appeal a jury's $1.67 billion patent infringement ruling in a case involving two blockbuster drugs that treat...
|
|
|
Four promising companies to watch
Based on strong product pipelines, positive clinical data and impressive partnerships with big drug companies, The Motley Fool profiles four small biopharm companies that could emerge as major players--and good investments.Array BioPharma...
|
|
|
Caliper Life Sciences Introduces Staccato Protein Workstation for Automated Protein Sample Preparation & Analy
- Caliper Addresses Key Bottlenecks in Quality by Design Initiative for Protein Therapeutics - HOPKINTON, Mass., June 29 Caliper Life Sciences, Inc.(NASDAQ:CALP) , a leading provider of tools and services for drug discovery and life...
|
|
|
Abbott plans to appeal $1.67 billion patent order
NEW YORK (AP) - Abbott Laboratories plans to appeal a jury's $1.67 billion patent infringement ruling in a case involving two blockbuster drugs that treat rheumatoid arthritis and other immune disorders.Late Monday, a jury in the Eastern...
|
|
|
Research and Markets Adds Report: Can Denosumab Achieve Superiority For The Prevention Of SREs In Cancer?
Research and Markets has announced the addition of the 'Can Denosumab Achieve Superiority For The Prevention Of SREs In Cancer?' report to its offerings.In a release, Research and Markets noted that report highlights include: There are...
|
|
|
[Head and Neck Cancer] Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symp
This Article Google Scholar Social Bookmarking Received June 26, 2008 Accepted February 9, 2009 Martin J.Schlumberger,* Rossella Elisei, Lars Bastholt, Lori J. Wirth, Renato G. Martins, Laura D. Locati, Barbara Jarzab, Furio Pacini,...
|
|
|
Abbott plans to appeal $1.67 billion patent order
NEW YORK (AP) - Abbott Laboratories plans to appeal a jury's $1.67 billion patent infringement ruling in a case involving two blockbuster drugs that treat rheumatoid arthritis and other immune disorders.Late Monday, a jury in the Eastern...
|
|
|
Abbott plans to appeal $1.67B patent order
NEW YORK Abbott Laboratories plans to appeal a jury's $1.67 billion patent infringement ruling in a case involving two blockbuster drugs that treat rheumatoid arthritis and other immune disorders.Late Monday, a jury in the Eastern...
|
|
|
Abbott to appeal $2.4b patent
NEW YORK - ABBOTT Laboratories plans to appeal a jury's US$1.67 billion (S$2.41 billion) patent infringement ruling in a case involving two blockbuster drugs that treat rheumatoid arthritis and other immune disorders.Late on Monday, a...
|
|
|
Abbott vows to appeal loss to Johnson & Johnson over patent case
NEW YORK - Abbott Laboratories plans to appeal a jury's $1.67 billion patent infringement ruling in a case involving two blockbuster drugs that treat rheumatoid arthritis and other immune disorders.Late Monday, a jury in the Eastern...
|
|
|
Abbott plans to appeal $1.67 billion patent order
NEW YORK (AP) - Abbott Laboratories plans to appeal a jury's $1.67 billion patent infringement ruling in a case involving two blockbuster drugs that treat rheumatoid arthritis and other immune disorders.Late Monday, a jury in the Eastern...
|
|
|
Jury finds Abbott infringed on J&J's patent; Abbott plans to appeal $1.67B ruling
Abbott Laboratories plans to appeal a jury's $1.67 billion patent infringement ruling in a case involving two blockbuster drugs that treat rheumatoid arthritis and other immune disorders.Late Monday, a jury in the Eastern District of...
|
|
|
Jury finds Abbott infringed on J&J's patent; Abbott plans to appeal $1.67B ruling
Jury finds Abbott infringed on J&J's patent; Abbott plans to appeal $1.67B ruling Marley Seaman, THE ASSOCIATED PRESS The Canadian Press, 2009 NEW YORK - Abbott Laboratories plans to appeal a jury's $1.67 billion patent infringement...
|
|
|
AMAG expects FDA action on anemia drug within days
* AMAG sees no outstanding issues * AMAG CEO confident Feraheme will win approval LOS ANGELES (Reuters) - AMAG Pharmaceuticals expects a decision on its injectable anemia drug in coming days, after not receiving a go-ahead from federal drug...
|
|
|
Abbott plans to appeal $1.67 billion patent order
NEW YORK (AP) - Abbott Laboratories plans to appeal a jury's $1.67 billion patent infringement ruling in a case involving two blockbuster drugs that treat rheumatoid arthritis and other immune disorders.Late Monday, a jury in the Eastern...
|
